Browsing by Subject "Coronary Disease"
Now showing 1 - 20 of 56
- Results Per Page
- Sort Options
Item Advances in the treatment of acute coronary syndromes(2001-02-01) Lange, Richard A.Item Anticoagulant therapy in coronary heart disease(1964-01-16) Bashour, Fouad A.Item Antithrombotic and thrombolytic therapy for coronary heart disease: consensus and controversy(1988-08-25) Smitherman, Thomas C.Item Assessment of risk for coronary heart disease(1999-10-14) Grundy, Scott M.Item Biodegradabable [sic] endovascular stents: fulfilling the mission and then stepping away(2006-10-20) Banerjee, SubhashItem The calcium antagonists -- new therapy for ischemic heart disease(1980-06-19) Roan, Peter G.Item Can coronary heart disease be eliminated from the population in our lifetime?(1996-05-23) Dietschy, John M.Item Cardiac rehabilitation of patients with coronary heart disease: a critical evaluation of its beneficial effects(1982-03-11) Mitchell, Jere H.Item A cardiologist's view of coronary artery surgery /(1972-04-06) Mullins, C. B. (Charles B.)Item Cardiovascular regulation in chronic heart failure(1983-11-03) Blomqvist, C. GunnarItem Catecholamines and adrenergic mechanisms: do they mediate certain consequences of ischemic heart disease?(1982-06-24) Willerson, James T.Item Cholesterol Efflux Capacity: Biological and Clinical Determinants in a Large Multi-Ethnic Population Study (Dallas Heart Study)(2018-01-23) Akinmolayemi, Oludamilola; Rohatgi, AnandBACKGROUND: Cholesterol efflux capacity characterizes the ability of HDL to accept cholesterol from extrahepatic cells in the periphery to the liver, which is a crucial step in reverse cholesterol transport. Cholesterol efflux capacity has been shown in clinical studies to be inversely correlated with prevalent coronary disease and incidence of cardiovascular events, but it is still unclear what biological and clinical determinants drive cholesterol efflux capacity. OBJECTIVES : To determine the biological and clinical variables that associate with cholesterol efflux capacity measured with two different methods in a large multi-ethnic population study (Dallas Heart Study 2) and how these associations differ by sex, race, history of diabetes, and history of cardiovascular disease. METHODS: Cholesterol efflux capacity was measured in the cohort (DHS-2) using both fluorescence (BODIPY) and radiolabeled methods. Statistical analysis was performed using Jonckheere-Terpstra trend test, Mann-Whitney test, and multivariate linear regression. Two-sided p values <0.05 were considered to indicate statistical significance. RESULTS: A total of 2373 participants were included. The median age was 51 years, 57% were women, 51% were black, 5% had history of CVD, and 17% had history of diabetes. Cholesterol efflux capacity measured by radiolabeled method was significantly higher in women than in men (P<0.001). Blacks had the lowest cholesterol efflux capacity measured by both BODIDY (p=0.010) and radiolabeled (p<0.001) methods. Participants without history of CVD had higher cholesterol efflux capacity measured by radiolabeled method compared to those with history of CVD (p=0.048). In multivariate regression, risk factors and circulating markers explained more of the variance in efflux using radiolabel than the variance in efflux using BODIPY (R2 0.195 vs. 0.099) with some overlapping and some distinct markers. Stratification by history of CVD, history of diabetes, race, and sex categories did not alter the findings. CONCLUSION: Our analysis revealed that biological and clinical variables that associate with cholesterol efflux capacity vary with measurement methods, but further studies with different study population validating these differences are needed. An understanding of these differences will be useful in identifying targets to improve cholesterol efflux capacity.Item Clustering of risk factors and the metabolic syndrome(1995-10-19) Grundy, Scott M.Item Coronary artery surgery -- 1975(1975-09-04) Lipscomb, KirkItem Coronary heart disease in women: natural history and significance of lipids as risk factors(1991-10-17) Denke, Margo A.Item Diabetes and coronary artery disease: therapy and outcomes(2000-09-07) Rutherford, John D.Item Disorders of plasma triglyceride metabolism(1981-01-22) Bilheimer, David W.Item Does gender bias compromise the treatment of women with coronary artery disease?(1995-09-07) Radford, Nina ButwellItem The Effect of a Disease Management Algorithm and Dedicated Postacute Coronary Syndrome Clinic on Achievement of Guideline Compliance: Results from the Parkland Acute Coronary Event Treatment Study(2008-06-13) Viswanathan, Sundeep; Yorio, Jeffrey T.; McGuire, Darren K.BACKGROUND: The application of disease management algorithms by physician extenders has been shown to improve therapeutic adherence in selected populations. It is unknown whether this strategy would improve adherence to secondary prevention goals after acute coronary syndromes (ACSs) in a largely indigent county hospital setting. METHODS: Patients admitted for ACS were randomized at the time of discharge to usual followup care versus the same care with additional visits with physician extenders in a dedicated post- ACS clinic. Physician extender visits were conducted according to a treatment algorithm based on contemporary practice guidelines. Groups were compared using the primary end point of achievement of low-density lipoprotein treatment goals at 3 months after discharge with key secondary endpoints including the achievement of additional evidence-based practice goals with up to 1 year of follow up assessment. RESULTS: One hundred forty consecutive patients were randomized. Rates of use of all evidencebased therapies assessed were high at the time of hospital discharge, and similar between the study groups. A similar proportion of patients returned for study follow-up in both groups at 3 months (54 [79%]/68 in the usual care group vs. 57 [79%]/72 in the intervention group; P = 0.97). Among those completing the 3-month visit, a low-density lipoprotein cholesterol level less than 100 mg/dL was achieved in 37 (69%) of the usual care patients compared with 35 (57%) of those in the intervention group (P = 0.43). There was no statistical difference in implementation of therapeutic lifestyle changes (smoking cessation, cardiac rehabilitation, or exercise) between groups. Prescription rates of evidence-based therapeutics at 3 months were similar in both groups. CONCLUSION: The implementation of a post-ACS clinic run by physician extenders applying a disease management algorithm did not measurably improve adherence to evidence-based secondary prevention treatment goals. Despite initially high rates of evidence-based treatment at discharge, adherence with follow-up appointments and sustained implementation of evidence-based therapies remains a significant challenge in this high-risk cohort.
- «
- 1 (current)
- 2
- 3
- »